| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Biomarkers of Congestion
|
Fudim, Marat
|
|
|
8 |
5 |
p. 398-400
|
artikel
|
| 2 |
Clinical Role of CA125 in Worsening Heart Failure
|
Núñez, Julio
|
|
|
8 |
5 |
p. 386-397
|
artikel
|
| 3 |
Correction
|
|
|
|
8 |
5 |
p. 428
|
artikel
|
| 4 |
Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea
|
Ibrahim, Nasrien E.
|
|
|
8 |
5 |
p. 415-422
|
artikel
|
| 5 |
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
|
Cunningham, Jonathan W.
|
|
|
8 |
5 |
p. 372-381
|
artikel
|
| 6 |
Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19
|
Abraham, William T.
|
|
|
8 |
5 |
p. 423-425
|
artikel
|
| 7 |
High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure
|
Yan, Isabell
|
|
|
8 |
5 |
p. 401-411
|
artikel
|
| 8 |
Instructions For Authors
|
|
|
|
8 |
5 |
p. A11-A15
|
artikel
|
| 9 |
Mediators of the Effects of Canagliflozin on Heart Failure
|
Lo, Kevin Bryan
|
|
|
8 |
5 |
p. 426
|
artikel
|
| 10 |
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial
|
Cunningham, Jonathan W.
|
|
|
8 |
5 |
p. 359-368
|
artikel
|
| 11 |
Natriuretic Peptides as Inclusion Criteria in Clinical Trials
|
Ibrahim, Nasrien E.
|
|
|
8 |
5 |
p. 347-358
|
artikel
|
| 12 |
Prediction of Incident Heart Failure
|
Gaggin, Hanna K.
|
|
|
8 |
5 |
p. 412-414
|
artikel
|
| 13 |
Reply
|
Heerspink, Hiddo J.L.
|
|
|
8 |
5 |
p. 427
|
artikel
|
| 14 |
Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials? ∗
|
Voors, Adriaan A.
|
|
|
8 |
5 |
p. 369-371
|
artikel
|
| 15 |
The Challenges of NT-proBNP Testing in HFpEF
|
Januzzi Jr., James L.
|
|
|
8 |
5 |
p. 382-385
|
artikel
|
Tijdschrift beschrijving